Streptococcus suis serotype 9 bacterin immunogenicity and protective efficacy

Veterinary Immunology and Immunopathology

Volumn 146, Issue 3-4, 2012, Pages 191-200

  Büttner, Nadine ^a   Beineke, Andreas ^a   de Buhr, Nicole ^a   Lilienthal, Sabrina ^a   Merkel, Jörg ^a   Waldmann, Karl Heinz ^a   Valentin Weigand, Peter ^a   Baums, Christoph Georg ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Basic membrane lipoprotein; MRP; Opsonophagocytosis; Serotype 9; Streptococcus suis

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIN; BACTERIUM ANTIBODY; BASIC MEMBRANE LIPOPROTEIN; IMMUNOGLOBULIN G; MURAMIDASE RELEASED PROTEIN; STREPTOCOCCUS SUIS SEROTYPE 9 BACTERIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; FIBRIN FORMATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MORBIDITY; MORTALITY; NONHUMAN; PIGLET; SEROCONVERSION; STREPTOCOCCUS SUIS; STREPTOCOCCUS SUIS SEROTYPE 9; SUPPURATION; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; EUROPE; HISTOCYTOCHEMISTRY; IMMUNIZATION; KAPLAN-MEIER ESTIMATE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS SUIS; SWINE; SWINE DISEASES;

STREPTOCOCCUS SUIS; SUIDAE;

EID: 84860371762     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2012.03.012     Document Type: Article

References (28)

1. Allgaier A., Goethe R., Wisselink H.J., Smith H.E., Valentin-Weigand P. Relatedness of Streptococcus suis isolates of various serotypes and clinical backgrounds as evaluated by macrorestriction analysis and expression of potential virulence traits. J. Clin. Microbiol. 2001, 39:445-453.
2. Baums C.G., Kaim U., Fulde M., Ramachandran G., Goethe R., Valentin-Weigand P. Identification of a novel virulence determinant with serum opacification activity in Streptococcus suis. Infect. Immun. 2006, 74:6154-6162.
3. Baums C.G., Valentin-Weigand P. Surface-associated and secreted factors of Streptococcus suis in epidemiology, pathogenesis and vaccine development. Anim. Health Res. Rev. 2009, 10:65-83.
4. Baums C.G., Kock C., Beineke A., Bennecke K., Goethe R., Schroder C., Waldmann K.H., Valentin-Weigand P. Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9. Clin. Vaccine Immunol. 2009, 16:200-208.
5. Beineke A., Bennecke K., Neis C., Schroder C., Waldmann K.H., Baumgartner W., Valentin-Weigand P., Baums C.G. Comparative evaluation of virulence and pathology of Streptococcus suis serotypes 2 and 9 in experimentally infected growers. Vet. Microbiol. 2008, 128:423-430.
6. De Greeff A., Hamilton A., Sutcliffe I.C., Buys H., van Alphen L., Smith H.E. Lipoprotein signal peptidase of Streptococcus suis serotype 2. Microbiology 2003, 149:1399-1407.
7. Dekker C.N., Bouma A., Daemen A.J., van Leengoed L.A., Jonker F.H., Wagenaar J.A., Stegeman J.A. Homologous whole bacterin vaccination is not able to reduce Streptococcus suis serotype 9 strain 7997 transmission among pigs or colonization. Vaccine 2012, 30:1379-1387.
8. Gottschalk M., Xu J., Calzas C., Segura M. Streptococcus suis: a new emerging or an old neglected zoonotic pathogen?. Future Microbiol. 2010, 5:371-391.
9. Higgins R., Gottschalk M. Streptococcal diseases. Diseases of Swine 2005, 769-783. Iowa State University, Ames, IA. B. Straw, S. D'Allaire, W. Mengeling, D. Taylor (Eds.).
10. Jacobs A.A.C., Van den Berg A.J.G., Loeffen P.L.W. Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis. Vet. Record 1996, 139:225-228.
11. Kock C., Beineke A., Seitz M., Ganter M., Waldmann K.H., Valentin-Weigand P., Baums C.G. Intranasal immunization with a live Streptococcus suis isogenic ofs mutant elicited suilysin-neutralization titers but failed to induce opsonizing antibodies and protection. Vet. Immunol. Immunopathol. 2009, 132:135-145.
12. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
13. Li Y., Gottschalk M., Esgleas M., Lacouture S., Dubreuil J.D., Willson P., Harel J. Immunization with recombinant Sao protein confers protection against Streptococcus suis infection. Clin. Vaccine Immunol. 2007, 14:937-943.
14. Mai N.T., Hoa N.T., Nga T.V., Linh, le D., Chau T.T., Sinh D.X., Phu N.H., Chuong L.V., Diep T.S., Campbell J., Nghia H.D., Minh T.N., Chau N.V., de Jong M.D., Chinh N.T., Hien T.T., Farrar J., Schultsz C. Streptococcus suis meningitis in adults in Vietnam. Clin. Infect. Dis. 2008, 46:659-667.
15. Rehm T., Baums C.G., Strommenger B., Beyerbach M., Valentin-Weigand P., Goethe R. Amplified fragment length polymorphism of Streptococcus suis strains correlates with their profile of virulence-associated genes and clinical background. J. Med. Microbiol. 2007, 56:102-109.
16. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. second ed.
17. Silva L.M., Baums C.G., Rehm T., Wisselink H.J., Goethe R., Valentin-Weigand P. Virulence-associated gene profiling of Streptococcus suis isolates by PCR. Vet. Microbiol. 2006, 115:117-127.
18. Smith H.E., Damman M., van der Velde J., Wagenaar F., Wisselink H.J., Stockhofe-Zurwieden N., Smits M.A. Identification and characterization of the cps locus of Streptococcus suis serotype 2: the capsule protects against phagocytosis and is an important virulence factor. Infect. Immun. 1999, 67:1750-1756.
19. Swildens B., Nielen M., Wisselink H.J., Verheijden J.H., Stegeman J.A. Elimination of strains of Streptococcus suis serotype 2 from the tonsils of carrier sows by combined medication and vaccination. Vet. Rec. 2007, 160:619-621.
20. Vecht U., Wisselink H.J., Jellema M.L., Smith H.E. Identification of 2 proteins associated with virulence of Streptococcus suis type 2. Infect. Immun. 1991, 59:3156-3162.
21. Vecht U., Wisselink H.J., van Dijk J.E., Smith H.E. Virulence of Streptococcus suis type 2 strains in newborn germfree pigs depends on phenotype. Infect. Immun. 1992, 60:550-556.
22. Wang Y., Dang Y., Wang X., Lu H., Wang X., Lang X., Li X., Feng S., Zhang F., Ren L. Comparative proteomic analyses of Streptococcus suis serotype 2 cell wall-associated proteins. Curr. Microbiol. 2011, 62:578-588.
23. Wertheim H.F., Nghia H.D., Taylor W., Schultsz C. Streptococcus suis: an emerging human pathogen. Clin. Infect. Dis. 2009, 48:617-625.
24. Wichgers Schreur P.J., Rebel J.M., Smits M.A., van Putten J.P., Smith H.E. Lgt processing is an essential step in Streptococcus suis lipoprotein mediated innate immune activation. PLoS ONE 2011, 6:e22299.
25. Wisselink H.J., Smith H.E., Stockhofe-Zurwieden N., Peperkamp K., Vecht U. Distribution of capsular types and production of muramidase-released protein (MRP) and extracellular factor (EF) of Streptococcus suis strains isolated from diseased pigs in seven European countries. Vet. Microbiol. 2000, 74:237-248.
26. Wisselink H.J., Vecht U., Stockhofe-Zurwieden N., Smith H.E. Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine. Vet. Rec. 2001, 148:473-477.
27. Zhang A., Xie C., Chen H., Jin M. Identification of immunogenic cell wall-associated proteins of Streptococcus suis serotype 2. Proteomics 2008, 8:3506-3515.
28. Zhang A., Chen B., Li R., Mu X., Han L., Zhou H., Chen H., Meilin J. Identification of a surface protective antigen, HP0197 of Streptococcus suis serotype 2. Vaccine 2009, 27:5209-5213.